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Abstract
In prion diseases, PrP
c, a widely expressed protein, is transformed into a pathogenic form called PrP
Sc, which is in itself
infectious. Antibodies directed against PrP
c have been shown to inhibit PrP
c to PrP
Sc conversion in vitro and protect in vivo
from disease. Other effectors with potential to eliminate PrPSc-producing cells are cytotoxic T cells directed against PrP-
derived peptides but their ability to protect or to induce deleterious autoimmune reactions is not known. The natural
tolerance to PrP
c makes difficult to raise efficient adaptive responses. To break tolerance, adenovirus (Ad) encoding human
PrP (hPrP) or control Ad were administered to wild-type mice by direct injection or by transfer of Ad-transduced dendritic
cells (DCs). Control Ad-transduced DCs from Tg650 mice overexpressing hPrP were also used for immunization. DC-
mediated but not direct administration of AdhPrP elicited antibodies that bound to murine native PrP
c. Frequencies of PrP-
specific IFNc-secreting T cells were low and in vivo lytic activity only targeted cells strongly expressing hPrP.
Immunohistochemical analysis revealed that CD3
+ T cell infiltration was similar in the brain of vaccinated and unvaccinated
139A-infected mice suggesting the absence of autoimmune reactions. Early splenic PrP
Sc replication was strongly inhibited
ten weeks post infection and mean survival time prolonged from 209 days in untreated 139A-infected mice to 246 days in
mice vaccinated with DCs expressing the hPrP. The efficacy appeared to be associated with antibody but not with cytotoxic
cell-mediated PrP-specific responses.
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Introduction
In prion diseases, cellular prion protein (PrP
c), a normal host
protein present in the majority of tissues and highly expressed in
the nervous system [1], is converted into a protease resistant form
(PrPres), also called scrapie PrP (PrP
Sc), which is in itself infectious
[2]. PrP
c is a protease sensitive glycoprotein which is attached to
the cell membrane by a glycophosphatidylinositol anchor. PrP
Sc
has a high b-sheet content and prone to aggregation. In the most
widely accepted model, PrP
Sc interacts with PrPc and converts it
into PrP
Sc [3]. Prion diseases are characterized by long
asymptomatic periods of incubation. Yet, it has been reported
that when PrP
Sc accumulation is stopped, PrP
Sc can be cleared,
injury is reduced by compensatory neuronal mechanisms and
synaptic function is restored [4], paving the way to therapeutics
aimed at blocking PrP
Sc accumulation.
Obtaining an effective prophylactic or therapeutic vaccines
against prion diseases combines the difficulties of developing
vaccines against persistent infections, and those inherent to
immunotherapy against self-antigens. Moreover, it remains
possible that protection against challenge versus to cure established
disease might involve different effectors. There is now good
evidence showing that anti-PrP antibodies are able to inhibit PrP
c
to PrP
Scconversion in vitro [5–8] and to protect mice against prion
disease in vivo providing they recognize native PrP
c [9–12]. While
the mechanism underlying their therapeutic effect has not yet been
elucidated one explanation is that antibodies alter PrP trafficking
and thereby inhibit the PrP
c to PrP
Sc conversion process [3].
However, it has been suggested that the main role of antibodies
was to diminish the pool of GPI-anchored PrP
c, thus leading to
protection or to a delay in animal death [13]. Opsonisation of
PrPSc by microglial cells may also be involved.
Other effectors with potential to eliminate PrP
Sc-producing cells
are cytotoxic T cells (CTLs) directed against PrP-derived peptides
but the repertoire of CD8
+ T cells in wild-type (wt) mice and their
ability to protect from prion disease or to induce deleterious
autoimmune reactions have never been addressed. In prion
infected mice, cells that replicate and accumulate PrP
Sc are
follicular dendritic cells (FDC) [14] while dendritic cells (DCs)
uptake and transport PrP
Sc [15] and participate in the process of
neuroinvasion [16]. Both cells are MHC class I positive; FDC
express naturally high level of PrP
c that became much stronger
after immune stimulation [17] and DCs upregulate its expression
upon in vivo maturation [18] and therefore might be target of
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Sc
accumulation could impair proteasome function and peptide
presentation by MHC I [19].
In addition to the above difficulties in identifing relevant
immune effectors, mechanisms maintaining peripheral tolerance
to self-PrP [20] present a major obstacle to the development of
vaccines with the risk of autoimmune diseases in cases of success.
We have previously shown that T cell tolerance can be overcome
in wt mice after PrP peptide immunization with oligo-CpG.
However, regarding B cell tolerance, the antibodies raised by this
protocol recognized recombinant but not native PrP
c [21–22]. B
cells specific for PrP epitopes exposed at the cell surface in the
native conformation of PrP
c were presumably deleted or anergized
in PrP expressing mice, and antibodies recognized only epitopes
buried in the PrP
c molecule [23]. These treatments were shown to
delay only moderately prion disease progression [24]. Despite
these observations, good evidence now exists that the anti-PrP
antibody repertoire is not totally deleted but that strong
immunogen delivery is necessary to break tolerance. PrP displayed
on retroviral particles induced humoral responses to self-native
PrP
c in wt mice [25]. In another report, a peptide containing a B
cell epitope (PrP144-152) of the murine PrP (mPrP) was inserted
into the L1 major capsid protein of the bovine papilloma virus and
used to immunize rabbits. These papillomavirus-like particles were
reported to induce autoantibodies that inhibited de novo synthesis
of PrP
Sc in cell culture [26]. Xenogenic antigens can, in some
instances, overcome tolerance to autoantigens. PrP is highly
conserved in mammals, among which 90% of the aminoacid
sequence is shared. Nevertheless vaccination with bovine PrP has
been shown to elicit antibodies that cross react with mPrP [27].
T epitopes can also be targeted by using xenoantigens:
immunization with human HER-2/neu peptide enhanced immu-
nity to a self-HER-2/neu CTL epitope and efficiently protected
against tumor growth [28]. Administration of recombinant
vaccinia virus encoding the human but not mouse homologue
(differing in the three HH-2-terminal aminoacids) of gp100
melanoma antigen to mice elicited a specific CD8
+ T cell response
and treated established B16 melanoma [29].
Tolerance in the PrP-specific CD4
+ Th compartment is likely to
be responsible for immune unresponsiveness. Thus to improve the
immunization procedure, we inserted human PrP (hPrP) into an
adenovirus vector that brings foreign Th specific for capsid proteins
and may be potent in generating antibody CD4
+ and CD8
+ CTL
responses against both the viral antigens and the transgene [30]. To
induce a potent immune response, prime-boost vaccination has been
used in view of the high immunogenicity of this strategy, as
demonstrated in several experimental models [31–33].
We show here that delivery to C57BL/6 (B6) wt mice of DCs
transduced with xenogenic PrP (i.e. human) encoded by an
adenoviral (Ad) vector is able to break immune B-cell tolerance
against the endogenous mPrP. The production of high levels of
antibody directed against the native conformation of mPrP
resulted in prion disease attenuation without triggering T cells,
thus avoiding autoimmune reactions.
Results
Immunization of wt mice with AdhPrP induces weak
immune responses against murine PrP and little increase
in survival time after scrapie challenge
We demonstrated in a previous study that cells transduced with
AdhPrP express a high level of hPrP, as shown by Western blotting
[34]. To generate an anti-PrP-specific immune response, priming
with AdhPrP and boosting with phPrP was performed. This
regimen was able to induce antibodies to native hPrP in both
Prnp
2/2 and C57BL/6 wt mice (Data S1). Following immuniza-
tion of B6 wt mice, sera were collected 2 weeks after the prime-
boost and tested by indirect immunofluorescence for the presence
of antibodies binding to mPrP on EL4 cells (Fig. 1A). After
immunization with AdhPrP but not with AdTA, Prnp
2/2 mice
developed an humoral response to native mPrP validating Ad
vectors as efficient immunogens. In wt mice, the level of the
humoral response for mPrP was nearly absent (Fig. 1A). A second
boost was performed 3 weeks after 139A challenge and raised
substantial amount of antibodies recognizing EL4 cells in only 2/7
wt mice. The epitope specificities recognized by serum antibodies
were identified by ELISA using libraries of overlapping mPrP
peptides (Table 1). Sera from Prnp
2/2 mice bound to the N-
Figure 1. Antibody response against native PrPc elicited in
Prnp
2/2 and C57BL/6 wt mice after direct Ad immunization. (A).
Sera collected after two or three immunizations with AdTA or AdhPrP
were tested (1/50 dilution) for their capacity to bind mPrP expressed on
activated EL4 cells. The level of serum binding was expressed as mean
fluorescence intensity (MFI) and revealed by incubation with a
biotinylated anti-Ig followed by APC-conjugated streptavidin. Fluores-
cence was analysed by flow cytometry. Each point represents the MFI of
an individual serum sample from immunized (triangle) or unimmunized
(black square) mice. (B). Epitope mapping of serum antibodies
generated after immunization. Individual immune sera (1/50 dilution)
were tested by ELISA for binding to each of mPrP peptides (10 mg/well)
coated on plastic microplates.
doi:10.1371/journal.pone.0004917.g001
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sera of wt mice recognized only P4 (PrP83-112) (Fig. 1B).
The T cell response was evaluated by measuring by ELISPOT
the precursor frequency of IFNc-secreting spleen cells upon
stimulation with the library of murine PrP peptides (Table 1).
Figure 2A shows that only one mouse out of two responded and
that the PrP-specific T cell response was directed against one
epitope lying in the murine P8 region. The T cell response to hPrP
peptides was weak (data not shown).
The in vivo lytic capacity of immunized mice was measured by
injecting CFSE
high C57BL/6 or Tg650 cells mixed with CFSE
low
Prnp
2/2 cells. AdhPrP-immunized mice were able to lyse 23% or
33% of target cells expressing hPrP, but unable to lyse cells
expressing mPrP (Fig. 2B). AdTA immunized-mice did not display
any cytotoxic activity. Thus, immunization with AdhPrP induced
an in vivo cytotoxic activity for hPrP overexpressing cells. These
results were confirmed by the absence of in vitro cytotoxic activity
for B6 targets in AdTA- or AdhPrP-vaccinated wt mice (data not
shown).
The effect of vaccination on the outcome of experimental
scrapie was examined after challenging wt mice i.p. with a 0.5%
139A brain homogenate 2 weeks after the prime-boost. Protection
against early PrP
Sc invasion was evaluated in the spleen of mice
collected 10 weeks post-infection (pi) by measuring the amount of
PK-resistant PrP (PrPres) by Western blot analysis of PTA
homogenates (Fig. 3). The 23–27 Kd band corresponding to
endogenous PrP
c prepared from normal spleen homogenate (Lane
2) was eliminated after PK treatment (Lane 3) confirming the
known sensitivity of PrP
c to proteases. Homogenates prepared
from a spleen from 139A-infected wt mice was resistant to PK
treatment. An inhibition of PrPres accumulation was observed in
one of two AdTA-treated mice (Lanes 5–6) and one of four
AdhPrP-treated mice (Lanes 7–10).
To quantify more precisely the effect of the different vaccination
protocols on the disease, we first studied the survival of control
mice as a function of the infectious dose of 139A scrapie
homogenates administered to C57BL/6 mice Table 2A showed
that mice receiving 0.5% 139A succumbed to the disease at
20968 dpi and that a 10- fold (0.05%) or 50- fold (0.01%) dilution
of the 139A homogenate prolonged the mean survival of 20 and
33 days, respectively. A low but significant delay of 13 and 22 days
was obtained in AdTA- and AdhPrP-vaccinated mice compared to
control mice challenged with 0.5% homogenate (p=0.002 and
p,0.0001, respectively;Table 2B). The mean incubation time and
the duration of the clinical stage were also longer in mice
immunized with AdhPrP than in untreated controls (5266v s
4168 days, p=0.007).
These results show that the direct administration of adenoviral
vectors encoding a xenogenic PrP into wt mice induces only a
marginal specific immunity against endogenous mPrP, showing
that tolerance remained virtually intact, and a moderate
prolongation of survival.
Immunization of C57BL/6 mice with adenovirus-
transduced DCs breaks immune tolerance and partially
protects mice against challenge
Immunization protocols can be based on Ad-transduced DCs
that are potent stimulators of CTL responses [35–36] and of T-
dependent antibody production [37–38]. In this assay, DCs from
C57BL/6 and Tg650 (overexpressing hPrP) were prepared from
bone marrow and maturated in the presence of GM-CSF and
LPS. DCs from Tg650 mice were transduced with AdTA
(DCTg650AdTA) and DCs from B6 mice with AdhPrP
(DCB6AdhPrP) or AdTA alone (DCB6AdTA). Up regulation of
class II (IAb) molecules was observed in CD11c
+ DCs from B6 and
Tg650 mice after maturation with LPS and was further amplified
following transduction with AdTA or AdhPrP (Fig. 4a). Expression
of B7.2 costimulatory molecule, detected with an anti-CD86 mAb,
increased after LPS-induced maturation, and furthermore follow-
ing transduction of DCs with AdhPrP (Fig. 4b). Transduction of
DCs from B6 mice with AdhPrP but not AdTA induced a high
expression of hPrP evidenced by 4F2 mAb staining in 30% of the
CD11c
+ DCs, while transduced and non- transduced CD11c
+DCs
from Tg650 mice expressed as expected a high level of hPrP in
100% of cells (Fig. 4c).
Mice were immunized twice with 5610
5 DCs and sera were
collected 2 weeks later. Sera from the three groups collected after
two immunizations, including mice immunized with DCB6AdTA,
stained EL4 murine cells (Fig. 5A). Mice were challenged i.p. with
the 0.5% (w/v) 139A brain homogenate and a third DC injection
was given 3 weeks later. Serum binding to EL4 cells was enhanced
Table 1. Comparative aminoacid sequences of overlapping peptides derived from murine PrP.
Murine
Peptides Aminoacid Sequences*
2 3 – 5 2 : P 1 KKRPKPGGW NTGGSRYPGQGSPGGNRYPP
39–67: P2 P G Q G S P G G N R Y P P Q G G –TWG QP HGG GWG QP
68–97: P3 H G G S WG QP HGGS WG QP HGGG WG QGG GT HN Q
83–112: P4 P H G G G W G Q G G G T H N QW NKPSKPKTNL KHV A
98–127: P5 W N K P S K P K T N L KHV AGAAAAGAVVGGLGGY
118–142: P6 G A V V G G L G G Y M L G S A M S R P M IH F G N
128–157: P7 M L G S A M S R P M IH F G N D W EDRYYRENM Y RYP
143–172: P8 D W EDRYYRENM Y RYPNQVYYRPV D Q YSNQN
158–187: P9 N Q V Y Y R P V D Q YSNQNNFVHDCVNI TI KQHT
173–189: P10 N F V H D C V N I T I K Q H T V T
1 9 3 – 2 1 8 : P 1 1 KGENFTETDVKM M ERVVEQM CV TQYQK
212–232: P12 M C V T Q Y QKESQ AYYDGRR S S S
*Bold characters represent the aminoacids that differ between murine and human PrP peptide sequences.
doi:10.1371/journal.pone.0004917.t001
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endogenous mPrP was higher and more homogeneous in mice
immunized with DCB6AdhPrP (mean fluorecence intensity (MFI):
248639) than with DCB6AdTA (mean MFI: 1106112), with
intermediate values being observed for DCTg650-treated mice
(mean MFI:1756108), suggesting that mPrP-specific responses
developed in wt mice. Linear epitope mapping showed that
antibodies produced in DCB6AdhPrP-treated mice weakly
recognized P1 and P4 but that no reactivity for PrP peptides
was detected in DCB6AdTA-treated mice. (Fig. 5B).
Spleen cells from mice immunized with DCB6AdhPrP secreted
IFNc in response to a broad spectrum of murine peptides while
mice treated with the DCTg650AdTA or DCB6AdTA developed
no significant response (Fig. 6A).
In vivo cytotoxicity was measured in immunized mice after
injection of B6 CFSE
high cells mixed with Prnp
2/2 CFSE
lowcells. A
low antigen-specific cytotoxicity (17%) for cells expressing mPrP
was observed in one of two mice immunized with DCB6AhPrP,
but not in mice immunized with DCB6AdTA or DCTg650AdTA
(Fig. 6B).
PrPres was measured by Western blot in the spleens of two mice
randomly chosen within each group at 10 weeks after infection
with the 0.5% suspension of 139A scrapie (Fig. 7). The amount of
PrPres in mice immunized with DCB6AdTA was similar to that
observed in untreated 139A mice (Lanes 5–6 vs Lane 4) while mice
that received DCB6AdhPrP or DCTg650AdTA mice had strongly
reduced levels of PrPres (Lanes 7–10).
Significant prolongation of both incubation and survival times
were observed in all vaccinated groups. The best result was
achieved after immunization with DCTg650AdTA (n=5) result-
ing in a 37 day increase in survival (p=0.0003) and in one mouse
remaining free of disease with no PrPres in its spleen at 300 dpi
(Table 2C). Mice immunized with DCB6AdPrP or DCB6AdTA
survived significantly longer than untreated mice (225612,
p=0.028 and 223616, p=0.008 versus 20968 dpi, respectively;
Figure 2. T cell responses in vaccinated C57BL/6 wt mice. (A).
Frequency of IFN-c secreting T cells in the spleens of immunized mice
evaluated by a ELISPOT assay. Spleen cells (10
6/well) from two
individual mice receiving AdTA or AdhPrP were stimulated 18 h at
37uC with each of 30-mer peptides from mPrP at a concentration of
10 mg/ml. The frequency of peptide-specific IFN-c secreting T cells was
calculated after substracting the mean number of spots obtained in the
absence of peptide. Each column shows the mean numbers of
spots6SD per 1610
6 spleen cells of triplicate cultures. (B–C). In vivo
cytotoxic activity was measured by flow cytometry: spleen cells from
mice vaccinated with AdTA or AdhPrP were collected 20 h after
injection of 10
7 CFSE
low Prnp
2/2 cells mixed with 10
7 CFSE
high cells
expressing either (B) mPrP (C57BL/6) or (C) hPrP (Tg650). Number of
CFSE
low and CFSE
high cells in the spleen of individual immunized mice
and percentage of specific lysis of PrP+ over Prnp
2/2 splenocytes were
calculated as detailed in ‘‘Materials and Methods’’.
doi:10.1371/journal.pone.0004917.g002
Figure 3. Measurement of PK-resistant PrPres in untreated and
AdTA- or AdhPrP-treated C57BL/6 wt mice. Western blotting was
performed on proteinase K (PK)-treated PTA precipitates prepared from
10 mg of spleens collected at 10 weeks after challenge with 0.5% 139A
scrapie. Samples were digested with 50 mg/ml PK, heated at 100Cu and
loaded on 12.5% polyacrylamide/SDS gel. Blots were incubated with 1/
5000 diluted SAF84 (Anti-mPrP mAb) and revealed with peroxidase-
conjugated goat anti-mouse Ig antibody. A. Lane 1=Molecular weight.
Lane 2=normal spleen. Lane 3=normal spleen+PK. Lanes 4=139A-
infected spleen+PK. Lanes 5–6=AdTA-treated infected spleen+PK.
Lanes 7–10=AdPrP-treated infected spleen+PK.
doi:10.1371/journal.pone.0004917.g003
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without clinical signs of disease and no PrPres in the spleen at 300
days. The duration of the clinical stage was not significantly
modified by the three treatments. Protection afforded by
DCB6AdPrP was not significantly better than that afforded by
DCB6AdTA, but vaccination with DCTg650AdTA prolonged the
incubation time (p,0.01) and the survival time (p=0.06)
compared to DCB6AdTA and DCB6AdPrP-treated groups.
T cell infiltration in the brains of vaccinated mice by
immunohistochemical analysis
To check for possible T cell infiltration, brains were collected
at 10 weeks dpi and at the terminal stage of the disease. Paraffin-
embedded tissue sections collected at 10 weeks were stained with
H&E and no signs of inflammation were detected (data not
shown). Brains collected at the terminal stage were stained with
anti-CD3 mAb by indirect immunofluorescence. Table 3
summarizes the mean numbers of CD3
+ cells counted in the
different regions of the brain of two mice per group. A small
number of CD3
+ T cells infiltrated all regions of brains but no
obvious differences were observed whatever mice were vacci-
nated or not.
Discussion
This study is based on an original methodology, in which a
xenogeneic antigen, hPrP, is presented either directly by
transgenic DCs together with adenovirus danger signals or via
adenoviral transduction. Using an adenoviral vector was based on
its known efficiency at eliciting CD8
+ T cells [35–36] and
antibodies [37–38] against self proteins.
Prime-boost immunization was performed by first injecting the
recombinant AdhPrP and then boosting with the PrP plasmid,
since other prime-boost regimens including AdhPrP-AdhPrP,
phPrP-AdhPrP (data not shown) or PcDNA encoding mouse PrP
[22–23] were unable to induce high-titer antibodies in C57BL/6
wt mice. In this study, Prnp
2/2 mice were immunized with
AdhPrP in parallel with wt mice to validate the Ad vectors and
immunization protocol in the absence of PrP tolerance. AdhPrP
was capable of raising antibodies specific for native mPrP in
Prnp
2/2 mice but only poorly in wt mice. Linear peptide mapping
identified in the sera of Prnp
2/2 mice antibodies specific for several
B-cell epitopes located in the N-terminal unstructured portion of
mPrP but only one located between aa 83 and 112 (P4) in the sera
of wt mice. These data are in agreement with those obtained with
Prnp
2/2 mice immunized with a PrP plasmid and confirmed that
wt mice have tolerized at least a part of the B cell repertoire
recognizing cell surface exposed epitopes [23].
The results were clearly different with DC vaccines that have
the capacity to break tolerance against a variety of self antigens
[36–39]. In our hands, BM-derived CD11
+ DCs from C57BL/6
mice transduced with AdhPrP or AdTA, as well as DCs from
Tg650 mice transduced with AdTA, were much more potent in
generating antibodies to native mPrP than direct immunization
with AdhPrP. However, almost no or few murine PrP peptides
(P1/P4) were recognized, suggesting that antibodies may bind to
Table 2. Comparison of incubation times, survival and clinical stage durations between non-immunized infected wt mice (A) or wt
mice immunized either (B) directly with AdTA or AdhPrP or (C) after transduction into DCs derived from C57BL/6 or Tg650 mice.
Treatment
139A dose
(100 mL) Incubation time Survival time
Clinical stage
duration
mean dpi6SD individual scores (dpi) mean dpi6SD mean dpi6SD
A-Dose Effect
a
Untreated 0,5% 16863 195-199-200-204-209-212-213-214-214-
215-216-221
209684 1 68
0,05% 17764 217-219-235-235-238 229610 5166
0,01% 19664 233-237-241-245-253-255 244694 7 69
B-Direct Injection
a
AdTA 0,5% 17565 218-220-221-221-226-226 222634 7 67
p
c=0.01 p
c=0.025 NS
c
AdhPrP 0,5% 17766 221-221-223-224-226-231-231-236-236-
236-240-249
231695 2 66
p
c=0.0005 p
c=0.0001 p
c=0.007
C-DC-Transduced
b
DCB6/AdTA 0,5% 179610 215-217-217-232-236-.300
d 223610 4867
p
c=0.049 p
c=0.008 NS
c
DCB6/AdhPrP 0,5% 18363 207-214-226-233-234-239 225612 43611
p
c=0.0001 p
c=0.023 NS
c
DCTg650/AdTA 0,5% 20167 227-240-255-262-.300
d 246616 44613
p
c=0.0003 p
c=0.001 NS
c
aMice were primed and boosted twice as described in Material and Methods and inoculated IP with 0.5% 139A brain homogenate two weeks after the second
immunization. Results are presented in days post infection (dpi)6SD.
bMice received three injections of 5610
5 DC as described in Material and Methods and were inoculated ip with 0.5% 139A brain homogenate one week after the second
immunization. Results are presented in days post infection (dpi)6SD.
cMann-Whitney Test; p significant compared to untreated mice: NS=non significant.
dOne mouse survived longer than 300 dpi and no PrPres was detected by Western Blot in the spleen at time of sacrifice.
doi:10.1371/journal.pone.0004917.t002
Ad-Vectored PrP Vaccination
PLoS ONE | www.plosone.org 5 March 2009 | Volume 4 | Issue 3 | e4917conformational epitopes not detectable by linear peptide ELISA.
This high production of antibodies specific for mPrP may be
related to the maturation state of DCs induced by LPS and Ad
vector transduction, which up-regulate MHC class II and B7.2
costimulatory molecules as shown in this study and also mPrP as
reported earlier [40]. During DCB6AdhPrP vaccination of B6
mice, an increased presentation of murine and human surface PrP
coexpressed on the same DC, together with exogenous help
directed against adenoviral proteins (attested by the presence of
antibodies against the hexon and fiber Ad proteins in the sera),
may have stimulated antibody production to self-PrP. High levels
of antibodies to self-mPrP were also elicited in 3 out of 6 recipients
receiving DCs from B6 mice transduced with the transactivator Ad
not expressing hPrP transgene (AdTA). In this situation, breaking
tolerance was probably achieved when matured DCs copresented
viral epitopes to CD4
+ Th cell and up-regulated surface mPrP to B
cells. Yet, the mechanism might be different in the course of
vaccination with DCTg650, since DCs express hPrP in the
mPrnp
2/2 context. It has been reported that DCs transduced with
Ad vectors produced type I IFN, which promoted the maturation
of both transduced and bystander DCs [41].
Direct AdhPrP vaccination protocol did not fully overcome
anergy, and was also inefficient at providing a good level of
protection against prion challenge. On the contrary, mice
immunized with DCTg650AdTA succumbed at 246 dpi; this
delay corresponded to the mean survival time of mice infected
with only 0.01% brain homogenate (244 dpi), as calculated from a
139A dose-effect study. These data clearly demonstrated that the
immune response to PrP after DC vaccination can inhibit PrP
Sc
replication in a very efficient manner as demonstrated by the
nearly absence of early accumulation of PrP
Sc in the spleen of
DCTg650AdTA-treated mice.
Compared to the multiple trials that have been undertaken to
actively generate systemic immune responses specific for PrP in wt
Figure 4. Expression of MHC class II, B7.2 and hPrP analysed by fow cytometry. BM-derived CD11c DCs prepared from C57BL/6 (left panel)
and Tg650 (right panel) mice before (- - -) and after LPS maturation ( ) and AdTA (. _ . _) or AdhPrP (.....) transfection. Cell surface expression of IAd (a),
CD86 (b) and hPrP (c) molecules. Staining controls (PE-conjugated anti-mouse IgG2a) are depicted in grey.
doi:10.1371/journal.pone.0004917.g004
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immunization strategies using DNA containing foreign helper T-
cell epitopes [42], repeated injection of xenogenic PrP peptides
conjugated to a carrier protein [43], peptides formulated in an
adjuvant derived from Mycobacterium [44] or multiple injection
of recombinant bovine PrP in complete Freund’s adjuvant [27]
largely failed to induce high levels of antibodies directed against
the native PrP and afforded modest increases in the average
survival time. Only mucosal immunization was able to induce
protection against a challenge delivered by the oral route,
probably linked to the induction of PrP antibodies at the mucosal
surfaces [45–48].
In light of these results, we tried to establish a relation between
the protection and the type or magnitude of anti-mPrP humoral
responses generated by different protocols of vaccination. Titers of
auto-antibodies that bind to mPrP-expressing cells were much
higher after DC vaccination compared to direct immunization
with AdhPrP. However, the reactivity of antibodies with linear
peptides in ELISA was low, suggesting that most of them
recognized conformational epitopes on mPrP molecule and
therefore might be efficient at blocking PrP
Sc replication. In these
trials, several observations suggest that the level of antibody
binding to membrane PrP
c is related to the level of protection:
mice displaying the highest antibody level either survived
(DCAdTA-treated mice) or had the longest survival (AdhPrP-
treated mice). It is noteworthy that while the evaluation of the
antibody level was not truly quantitative, it did allow comparison
of the intensity of binding of all serum samples, since results
presented were obtained in the same assay for all experiments.
Nevertheless, the binding capacity of antibodies on whole PrP
c
does not necessary parrallel the neutralizing activity, which could
implicate specific epitopes, and thus not predictive of in vivo
protection.
Regarding the safety of prion vaccines, very few studies have
concerned the identification or generation of CD8
+ CTLs against
self-PrP
c and thus their possible impact in prion disease or
inducing deleterious autoimmunity. In two published vaccination
trials, PrP-specific CD4
+ and CD8
+ T cells were induced as
determined by detection of intracellular IFNc [49–50]. The
treatment dramatically delayed the onset of prion disease when
given intracerebrally, although after the first symptoms appeared,
it progressed rapidly. The authors attributed the deleterious effect
to antibody-mediated neuronal damage but did not analyse the
possible contribution of PrP-specific CTLs [49]. In the present
study, direct AdhPrP immunization induced a variable frequency
of precursor T cells secreting IFNc in response to P8 that contains
the major CD4
+ epitope 155–170 of mPrP [21–22]. The weakness
of T cell responses could be explained by tolerance to mPrP and/
or by preferential priming of Th cells directed to viral capsid
proteins. This immunization procedure induced a significant in
vivo cytotoxicity for target cells overexpressing hPrP but not for
cells normally expressing mPrP. The lack of cytotoxicity for self-
PrP may be due either to an absence of murine MHC class I
epitopes shared between mPrP and hPrP, or to a low TCR affinity
of these cells which was insufficient for lysis of target cells
expressing a physiological level of mPrP. Furthermore, we may not
be certain that CD8
+ T cells were responsible for the in vivo lysis
of CFSE-labeled targets, since effectors were not identified in this
assay. Adoptive transfer experiments are currently done to answer
these questions. In contrast, DC vaccine strategy did not generate
significant T cell responses specific for mPrP. Some CD3
+ T cells
were found in the brain of 139A-infected mice at the terminal
stage of the disease but similar numbers were detected whether or
not mice were vaccinated. Similarly, it has been reported that in
the absence of previous vaccination, CD8
+ T cells specific for PrP,
without CTL activity, infiltrate the brain of intracranially infected
mice [51]. Collectively, the in vivo and in vitro data strongly
suggested that cytotoxic cells did not participate in the partial
protection demonstrated here, and did not induce inflammatory
reactions in the brain.
In conclusion, our results show that DCs were very potent at
breaking tolerance against endogenous mPrP and favor the
production of high titered antibodies against its native conforma-
tion over T-cell responses resulting in substantial delay in disease
progression without triggering autoimmune reactions. The
underlying mechanism may be related to a high expression of
membrane mPrP on mature DCs temporally coupled with the
generation of a strong helper response elicited by viral vector
antigens. During the past years, numerous clinical trials have been
Figure 5. Antibody response against native PrPc elicited in
C57BL/6 wt mice after DC vaccination. (A). Sera collected after two
or three immunizations with DCB6AdTA, DCB6AdhPrP or DCTg650AdTA
were tested (1/50 dilution) for their capacity to bind mPrP expressed on
activated EL4 cells. The level of serum binding was expressed as MFI
revealed by incubation with a biotinylated anti-Ig antibody followed by
APC-conjugated streptavidin. Fluorescence was analysed by flow
cytometry. Each point represents the MFI obtained for an individual
serum sample from immunized (triangle) or unimmunized (black
square) mice. (B). Epitope mapping of serum antibodies generated
after immunization. Individual immune sera (1/50 dilution) were tested
by ELISA for binding to each 30-mer mPrP peptides (10 mg/well) coated
on plastic microplates. Each bar is the mean OD6SE of five or four sera
from mice immunized with DCB6AdTA, DCB6AdhPrP or DCTg650AdTA,
respectively.
doi:10.1371/journal.pone.0004917.g005
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vaccines for a broad range of malignant diseases and potent anti-
tumor immune responses together with the absence of toxicity and
autoimmunity were recorded [52]. The high levels of antibody and
absence of autoimmunity observed in our work make DC vaccines
a promising therapeutic strategy that might be applied in
neurodegenerative diseases such as Alzheimer.
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the local
ethics committee of ENVA (Ecole Ve ´te ´rinaire d’Alfort).
Mice
C57BL/6 mice from Charles Rivers and Prnp
2/2 mice knock
out for the murine Prnp gene on a C57BL/6 background (donated
by Dr. Charles Weissmann, Institut of Neurology, Medical Research
Concil Prion unit, London, UK) were used for immunization and as
recipients for cell transfer experiments. For preparation of DCs,
Tg650 transgenic mice overexpressing hPrP with methionine at
codon 129 on a mouse Prnp
2/2 background [53] were kindly
provided by Hubert Laude (Jouy en Josas, France).
Vectors, immunisation protocols and prion challenge of
mice
An adenovirus type 5 (AdTRMet) expressing the hPrP has been
previously described [34]. The PrP gene is under the control of the
tetracycline-responsive promoter, allowing tight regulation of PrP
expression. The AdCMNtTA (AdTA) virus encoding the transacti-
vator of the tetracycline-regulated system, under the control of the
CMV promoter and in fusion with a nuclear localisation signal, was
kindlyprovidedbyDr.H.Hamada(CancerInstitute,Tokyo,Japan).
Immunization of C57BL6 mice or Prnp
2/2 mice was conducted by
inoculation of a mixture of equal doses of each virus (AdTRMet /
AdCMNtTA and referred as AdhPrP) by the intramuscular route.
The mixture was always prepared immediately prior to inoculation
of mice. This immunization strategy was chosen at the request of a
French regulatory body, as a mean of diminishing the risk of
bystandergenetransferbya vectorexpressing hPrP ata high level.A
boost was administered 3 weeks laterbyintramuscularinoculation of
50 mg of pAdTRMet [34], a plasmid harbouring the same PrP
transcription unit as AdTRMet together with 50 mgo fp T A
encoding the transactivator of the tetracycline-regulated system
Figure 6. T cell responses in DC-vaccinated C57BL/6 wt mice. (A). Frequency of IFN-c secreting T cells in the spleens of immunized C57BL/6
B6 mice evaluated by ELISPOT assay. Spleen cells (10
6/well) from mice receiving DCB6AdTA, DCB6AdhPrP or DCTg650AdTA were stimulated 18 h at
37uC with each 30-mer peptides from mPrP at a concentration of 10 mg/ml. The frequency of peptide-specific IFN-c secreting T cells was calculated
after subtracting the mean number of spots of triplicate cultures obtained in the absence of peptide. Each column shows the mean numbers of
spots6SE per 5610
5 spleen cells from two, four or six mice that received DCB6AdTA, DCB6AdhPrP or DCTg650AdTA, respectively. (B). In vivo
cytotoxic activity was measured by flow cytometry: spleen cells from mice vaccinated with DCB6AdTA, DCB6AdhPrP or DCTg650AdTA were collected
20 h after injection of 10
7 CFSE
low Prnp
2/2 cells mixed with 10
7 CFSE
high cells expressing mPrP (B6). (C). Number of CFSE
low and CFSE
high cells in the
spleen of vaccinated or not individual mice and percentage of specific lysis of PrP
+ over Prnp
2/2 splenocytes calculated as detailed in ‘‘Materials and
Methods’’.
doi:10.1371/journal.pone.0004917.g006
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referred as phPrP. Control mice were inoculated with AdTA or
pTA. Another immunization protocol used DCs prepared as
described below. DCs from C57BL/6 mice were transduced with
AdTA (DCB6AdTA) or AdTA/AdhPrP (DCB6AdhPrP) and DCs
from Tg650 mice were transduced with AdTA alone (Tg650AdTA).
C57BL/6 mice received 5610
5 DCs intraperitoneally at weeks 0
and 3. Immunization was repeated once three weeks after prion
challenge. All experiments were conducted according to the rules of
the local ethical committee of the Alfort veterinary school. All
animals were identified individually by a transponder. Mice were
challenged two weeks after the second immunization by the
intraperitoneal route with 100 ml of 0.5% homogenate prepared
from terminal 139A-scrapie brain, corresponding to 104.33 ID50
[54].The dosageof 0.05%and 0.01%139A brainhomogenatewere
assessed in survival experiments. The progression of the disease was
monitored by observing twice a week starting at 20 weeks post
infection (p.i.), activity levels and competenceon a set of parallel bars
as described previously [54].
Murine DCs and adenoviral transduction
DCs were generated from bone marrow of C57BL/6 or Tg650
mice. Cells were resuspended at 10
6 cells/ml in RPMI 1640
supplemented with 10% heat inactivated FCS, 1000 u of
recombinant GM-CSF (Peprotech, France), glutamine, sodium
pyruvate HEPES, 50 mM 2-ME, penicillin and streptomycin and
cultured at 37uC in a 5% CO2 for 3 days. Cells were provided with
fresh medium containing GM-CSF, harvested 2 days later and
washed. For transduction, AdhPrP was used at a multiplicity of
infection of 100. DCs were matured by adding LPS at 2 mg/ml for
20 h. The transduction efficiency of the DCs was determined by
flow cytometry using the anti-hPrP 4F2 mAb. Surface markers of
CD11c
+ DCs were analysed by indirect immunofluorescence using
antibodies against IAb and B7-2 molecules.
ELISPOT Assay
The number of antigen-specific IFNc producing cells was
evaluated in the spleens of immunized mice by ELISPOT assay.
Briefly, nitrocellulose-based 96-well plates (Millipore) were coated
with anti-mouse IFNc capture Abs (1/500) (Becton Dickinson) for
2ha t3 7 uC, followed by an overnight incubation at 4uC. Plates were
washed with PBS-0.05% Tween 20 (PBS-T) and blocked with
medium containing 10% FCS for 2 h at 37uC. Responders from
individual mice were seeded at 10
6 cells/well for total splenocytes and
stimulated with medium or 10 mg/ml of each peptides from a library
of murine overlapping 30-mer PrP peptides (Table 1). Plates were
incubated at 37uCi n5 %C O 2 f o r2 4h ,w a s h e dw i t hP B S - T ,a n d
then incubated for 2 h at 37uC with biotinylated anti-mouse IFNc
detection Abs (Becton Dickinson). After washing, alkaline phospha-
tase conjugated to streptavidin was added (Roche) (1/500 dilution,
100 ml/well) for 2 h. Secreting cells were visualized using tetrazolium
nitroblue/bromochloro-indolylphosphate (TNB/BCIP) substrate
(Promega) and spots were counted using an automatic ELISPOT
plate reader (ICI). Test wells were assayed in triplicate and the
frequency of peptide-specific T cells was calculated after subtracting
the mean number of spots obtained in the absence of peptide. A
frequency of spots below 20 was considered as non significant.
Antibody titration (ELISA)
Plates (Maxisorp, Nunc) were coated with 10 mg/ml of
murine 30-mer PrP peptides (Table 1) in 0.1 M sodium
carbonate buffer overnight at 4uC, washed with PBS and
blocked with 1% non-fat milk in PBS-T for 2 h at 37uC. Sera
were diluted 1:50 and added in duplicate and incubated
overnight at 4uC. After washing, 200 mlo fp e r o x i d a s e
conjugated anti-mouse Ig (1/5000) was added and left 2 h at
room temperature. Plates were washed and 200 ml/well of
freshly prepared H2O2/ O-phenylediamine (OPD) substrate
solution (Sigma) was added. The reaction was stopped with
sulfuric acid (2N) and plates were read at 492 nm.
Table 3. Immunohistochemical analysis of T cell infiltration in the brains of untreated or vaccinated mice.
Regions Mean number (6SD) of CD3
+ T cells infiltrating brains of 139A infected mice
Untreated AdTA AdhPrP DCB6AdTA DCB6AdhPrP DCTg650
Anterior 2.4560.07 3.2460.7 4,1261.86 2.7460.1 2.8360.42 3.6361.06
Median 4.1260.17 4.4560.78 6.6660.17 4.5060 5.6760.19 4.0561.87
Posterior 3.2561.76 3.1960.73 2.6660.01 1.9560.15 4.2261.35 2.6360.35
Mean number of CD3
+ infiltrating/brain area.
doi:10.1371/journal.pone.0004917.t003
Figure 7. Measurement of PK-resistant PrPres in untreated and
DCB6AdTA-, DCB6AdhPrP- or DCTg650AdTA-vaccinated
C57BL/6 wt mice. Western blotting was performed on PK-treated
PTA precipitates prepared from 10 mg of spleens collected at 10 weeks
after challenge with 0.5% 139A scrapie. Samples were digested with
50 mg/ml PK, heated at 100uC and loaded on 12.5% polyacrylamide/SDS
gel. Blots were incubated with 1/5000 diluted SAF84 (Anti-mPrP mAb)
and revealed with peroxidase-conjugated goat anti-mouse Ig antibody.
Lane 1=Molecular weight. Lane 2=normal spleen. Lane 3=normal
spleen+PK. Lane 4=139A-infected spleen+PK. Lanes 5–6=DCB6TA-
treated infected spleen+PK. Lanes 7–8=DCB6AdPrP-treated infected
spleen+PK. Lanes 9–10=DCTg650AdTA-treated infected spleen+PK.
doi:10.1371/journal.pone.0004917.g007
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Prnp
2/2 transfected EL4 T cells expressing murine PrP (mPrP)
as previously published [22] were used as target for testing serum
antibodies specific binding in indirect immunofluorescence. EL4
cells were activated overnight on anti-CD3 antibody coated-plastic
(2-C11, 10 mg/ml) before testing immune sera for maximal
expression of PrP
c. Non transfected wt EL4 T cells, even upon
activation, express only weak levels of cell surface PrP
c
(unpublished observations). The level of hPrP and mPrP
expression was checked by indirect immunofluorescence using
4F2 and SAF83 mAb, respectively (from Dr. Grassi, CEA,
France). After blocking Fc receptors with antibody 2.4G2 for
20 min at 4uC in FACS buffer, cells were incubated with control
or immune sera diluted 1/10 or 1/50 for 20 min at 4uCa n d
washed and PE-labelled anti-mouse Ig was then added for
20 min. To increase the sensitivity of serum antibody detection
on EL4 cells, revelation was performed using a biotinylated rat
anti-mouse IgG and streptavidin-APC (BD Biosciences) as
second antibody. Sera from peptide-immunized mice were
considered significantly positive for native PrP binding when the
mean fluorescence intensity (MFI) was greater than the
MFI+3SD obtained with sera from normal mice. The specificity
of this assay for detecting anti-native PrP
c Ab was previously
validated on non-transfected EL4 cells activated under the same
conditions as transfected EL4 cells. MHC class II, B7.2 and
hPrPmolecule expression was quantified at the surface of DCs
before and after in vitro maturation and transduction with
AdTA or AdhPrP. Anti-IAd, anti-CD86 (BD Biosciences) and
anti-hPrP mAbs were incubated after Fc receptor blocking with
DCs and revealed with PE-conjugated anti-mouse IgG2a mAb.
After washing, cells were analysed on a FACS-calibur flow
cytometer using Cell Quest software (Becton-Dickinson)
In vivo cytotoxicity test
Cytolytic T cells were detected by in vivo clearance of CFSE-
stained target cells expressing murine or human PrP or no PrP.
Control target splenocytes from Prnp
2/2 mice were stained with
0.5 mM CFSE (CFSE
low) (Vybrant CFDA SE Cell Tracer Kit;
Molecular Probes). Antigen-specific target splenocytes from
C57BL/6 (mPrP) or Tg650 (over expressing hPrP) mice were
stained with 5.0 mM CFSE (CFSE
high). Equal numbers of CFSE-
labelled control and experimental target splenocytes (10610
6
each, mixed 1:1) were injected iv into immunized recipient and
control naive mice. Eighteen hours after CFSE-labelled target cell
injection, splenocytes from recipients were collected, red blood
cells lysed and analyzed by flow cytometry, gating on CFSE-
positive splenocytes. The percentage of specific cytotoxicity was
calculated using the following formula:[12(CFSE
highexp/(CFSE
low
exp+CFSE
highexp)/(CFSE
highcontrol/(CFSE
lowcontrol+CFSE
high
control)]6100 in which #CFSE
high represents the number of
antigen-specific target cells and #CFSE
low represents the
number of control target cells recovered from either naive or
immunized mice.
Western blot analysis of PrPres
10% spleen homogenates were centrifuged 1 min at 1000 rpm.
500 ml of supernatant was mixed with an equal volume of 4%
sarkosyl in PBS pH 7.4 and digested with 50 u/ml Benzonase
(Benzon nuclease, purity 1; Merck) for 30 min at 37uC. Samples
corresponding to 10 mg of spleen were precipitated with 0.3%
sodium phosphotungstic acid (PTA) at 37uC for 30 min and pellets
were resuspended in 20 ml PBS 0.1% sarkosyl. Samples were
digested with 20 mg/ml proteinase K (PK) at 37uC for 15 min,
blocked by addition of loading buffer (125 mM Tris pH 6.8, 20%
glycerol, 4% 2-ME, 8 mM 4-(2-aminoethyl)-benzene sulfonyl
fluoride, and 0.02% bromophenol blue) and heated at 100uC for
10 min. After electrophoresis in a 12.5% polyacrylamide/SDS gel,
proteins were electrotransferred onto a PVDF membrane and
blocked in 5% non-fat milk in 0.1% PBS-T. Blots were incubated
overnight at 4uC in a 1/30000 dilution of anti-PrP mAb (SAF83),
then for 1 h with peroxidase-conjugated goat anti-mouse IgG
antibody, and finally proteins were revealed by chemolumines-
cence (ECL
+, Amersham).
Checking for autoimmune-related pathology
Brains were collected immediately after sacrifice and immer-
sion-fixed in 4% para-formaldehyde. They were transversally cut
into three equal, anterior, median and posterior and embedded in
paraffin. Five mm-thick sections were cut on a Leica RM2145
microtome and deposited on Superfrost Menzel-Glaser slides and
then air dried. Evaluation of lesions was done by a certified
veterinary pathologist. Haematoxylin/eosin (H&E) staining was
performed on embedded paraffin sections of brains collected 10
weeks after challenge and immunofluorescence staining on brains
collected at terminal stage of the disease. To detect T cells, a 1/
200 diluted anti-CD3 mAb clone SP7 (Thermo Scientific,
Interchim) was incubated for 30 min and then revealed with a
FITC-goat anti-rabbit IgG (Jackson, Interchim) at 1/200 dilution
for 30 min. Slides were mounted in Vectashield fluorescent-
mounting medium containing Dapi stain to confirm the presence
of cells (Vector Laboratories, Burlingame, CA). Photomicrographs
were taken with a Olympus BX61 fluorescent microscope and
analysed with Gimp software. Two mice per treatment were
examined and the number of CD3
+ cells was quantified by
counting five foci at 4006magnification in three sections for each
brain sector.
Statistical Analyses
Comparison of the mean incubation time, survival or duration
of clinical stages was performed with the Mann-Whitney test.
Mean precursor frequencies were compared using the Student’s t
test.
Supporting Information
Data S1 Antibody response against native PrPc elicited in
Prnp2/2 and C57BL/6 wt mice after direct Ad immunization.
Sera collected after two or three immunizations with AdTA or
AdhPrP were tested (1/50 dilution) for their capacity to bind
human PrP expressed on C5 cells. The level of serum binding was
expressed as mean fluorescence intensity (MFI) and revealed by
incubation with a biotinylated anti-Ig followed by APC-conjugated
streptavidin. Fluorescence was analysed by flow cytometry. Each
point represents the MFI of an individual serum sample from
immunized (triangle) or unimmunized (black square) mice.
Found at: doi:10.1371/journal.pone.0004917.s001 (0.05 MB TIF)
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